X

Trial Profile

An Open Label, Phase II Study to Investigate DSA Rebound in Patients With a Positive Crossmatch, Made Transplantable With Imlifidase

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 04 Sep 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Belatacept (Primary) ; Bortezomib (Primary) ; Imlifidase (Primary) ; Rituximab (Primary) ; Immune globulin
Indications Renal transplant rejection
Focus Therapeutic Use
Sponsors Hansa Biopharma AB

Most Recent Events

30 Aug 2024 Status changed from active, no longer recruiting to discontinued.
30 Nov 2023 Status changed from recruiting to active, no longer recruiting.
21 Dec 2022 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com